The current financial score of Sophia Genetics SA is 6.76. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 23.31M, representing a year-over-year increase of 27.22%, while its net profit experienced a year-over-year increase of 0.26%.
The current valuation score of Sophia Genetics SA is 8.07. Its current P/E ratio is -6.66, which is -78.22% below the recent high of -1.45 and -13.34% above the recent low of -7.55.
The current earnings forecast score of Sophia Genetics SA is 8.80. The average price target is 9.75, with a high of 14.00 and a low of 7.00.
The current price momentum score of Sophia Genetics SA is 3.85. Currently, the stock price is trading between the resistance level at 8.77 and the support level at 7.19, making it suitable for range-bound swing trading.
The current institutional shareholding score of Sophia Genetics SA is 3.00. The latest institutional shareholding proportion is 38.63%, representing a quarter-over-quarter decrease of 2.63%. The largest institutional shareholder is Akre Capital Management, holding a total of 3.72M shares, representing 0.42% of shares outstanding, with 120.67% increase in holdings.
The current risk assessment score of Sophia Genetics SA is 4.41. The company's beta value is 0.99. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.